Annual Report
2022
Menu
Search
Annual Report
2022
Menu
Main menu
argenx Group
argenx Group
Shareholder Letter
2022 In Brief
2023 Outlook
Company Profile
Strategy and Objectives
Our Products and Product Candidates
Our Products and Product Candidates
VYVGART
Efgartigimod Development
Efgartigimod Indications
ARGX-117 Development
Immunology Innovation Program
Collaboration Agreements
License Agreements
Distribution Agreements
Manufacturing and Supply
Intellectual Property
Regulation
Regulation
Licensure and Regulation of Biologics in the U.S.
Regulation and Procedures Governing Approval of Medicinal Products in the EU and the UK
Regulation and Procedures Governing Approval of Medicinal Products in Japan
Coverage, Pricing and Reimbursement
Government Pricing and Reimbursement Programs for Marketed Drugs in the U.S.
Healthcare Law and Regulation
Healthcare Reform
Environmental Issues which may Influence the Use of our Material Fixed Assets
Risk Factors
Risk Factors
Financial Position and Additional Capital
Commercialization
Other Government Regulations
Development and Clinical Testing
Dependence on Third Parties
Business and Industry
Intellectual Property
Organization and Operations
Corporate Governance
Corporate Governance
Dutch Corporate Governance Code
Management Structure
Management Structure
General
Statement of the Board of Directors
Board of Directors
Non-Executive Directors
Senior Management
Confirmation of No Past Offenses
Conflict-of-Interest Transactions
Code of Business Conduct and Ethics
Report of the Non-Executive Directors
Remuneration Report
Remuneration Report
Remuneration Policy
Reference Group and Setting Reward Levels
Remuneration Components of our Senior Management Team Compensation
Executive Remuneration
Remuneration of Non-Executive Directors
Pay Ratios Within the Company
Long-Term Incentives Granted to Key Persons – Equity Incentive Plan
Risk Appetite & Control
Share Capital
Share Capital
Legal Information on the Company
Share Capital
Share Classes and Principal Shareholders
General Meeting and Voting Rights
Anti-Takeover Provisions
Amendments of Articles of Association
Transparency Directive
Dutch Financial Reporting Supervision Act
Dividends and Other Distributions
Financial Calendar 2023
Financial Review
Financial Review
Overview
Basis of Presentation
Capitalization and Indebtedness
Critical Accounting Estimates and Judgments
Results of Operation
Liquidity and Capital Resources
Off-Balance Sheet Arrangements
Contractual Obligations
Information Regarding the Independent Auditor
Material Contracts and Related Party Transactions
Employees
Legal and Arbitration Proceedings
Insurance
Financial Statements
Financial Statements
Consolidated Financial Statements
Consolidated Financial Statements
Consolidated Statements of Financial Position
Consolidated Statements of Profit or Loss
Consolidated Statements of Comprehensive Income and Loss
Consolidated Statements of Cash Flows
Consolidated Statements of Changes in Equity
Notes to the Consolidated Financial Statements
Notes to the Consolidated Financial Statements
1.
General Information about the Company
2.
Significant Accounting Policies
3.
Critical Accounting Judgements and Major Sources of Estimation Uncertainty
4.
Property, Plant and Equipment
5.
Intangible Assets
6.
Deferred Taxes
7.
Other Non-Current Assets
8.
Inventories
9.
Trade and Other Receivables
10.
Financial Assets — Current
11.
Cash and Cash Equivalents
12.
Share Capital and Share Premium
13.
Share-Based Payments
14.
Trade and Other Payables
15.
Product Net Sales
16.
Collaboration Revenue
17.
Other Operating Income
18.
Segment Reporting
19.
Research and Development Expenses
20.
Selling, General and Administrative Expenses
21.
Personnel Expenses
22.
Leases
23.
Financial Result and Exchange Gains/ (Losses)
24.
Income Tax Expense
25.
Loss per Share
26.
Financial Risk Management
27.
Related Party Transactions
28.
Contingencies
29.
Commitments
30.
Audit Fees
31.
Overview of Consolidation Scope
32.
Events After the Balance Sheet Date
Company Financial Statements
Company Financial Statements
Signatures of Executive and Non-Executive Directors
Company Financial Statements for argenx SE
Notes to the Company Financial Statements
Other Information
Independent Auditor’s Report
Non-Financial Information
Non-Financial Information
Regulations and Compliance
NFRD
EU Taxonomy
Patient Stories
Glossary
Glossary
Cross Reference table for annual reporting requirement
Management Confirmations
Definitions
Quick links
Patient Stories
Year 2022 in Brief
Outlook for Year 2023
Download center
argenx Group
argenx Group
Shareholder Letter
2022 In Brief
2023 Outlook
Company Profile
Strategy and Objectives
Our Products and Product Candidates
Our Products and Product Candidates
VYVGART
Efgartigimod Development
Efgartigimod Indications
ARGX-117 Development
Immunology Innovation Program
Collaboration Agreements
License Agreements
Distribution Agreements
Manufacturing and Supply
Intellectual Property
Regulation
Regulation
Licensure and Regulation of Biologics in the U.S.
Regulation and Procedures Governing Approval of Medicinal Products in the EU and the UK
Regulation and Procedures Governing Approval of Medicinal Products in Japan
Coverage, Pricing and Reimbursement
Government Pricing and Reimbursement Programs for Marketed Drugs in the U.S.
Healthcare Law and Regulation
Healthcare Reform
Environmental Issues which may Influence the Use of our Material Fixed Assets
Risk Factors
Risk Factors
Financial Position and Additional Capital
Commercialization
Other Government Regulations
Development and Clinical Testing
Dependence on Third Parties
Business and Industry
Intellectual Property
Organization and Operations
Corporate Governance
Corporate Governance
Dutch Corporate Governance Code
Management Structure
Management Structure
General
Statement of the Board of Directors
Board of Directors
Non-Executive Directors
Senior Management
Confirmation of No Past Offenses
Conflict-of-Interest Transactions
Code of Business Conduct and Ethics
Report of the Non-Executive Directors
Remuneration Report
Remuneration Report
Remuneration Policy
Reference Group and Setting Reward Levels
Remuneration Components of our Senior Management Team Compensation
Executive Remuneration
Remuneration of Non-Executive Directors
Pay Ratios Within the Company
Long-Term Incentives Granted to Key Persons – Equity Incentive Plan
Risk Appetite & Control
Share Capital
Share Capital
Legal Information on the Company
Share Capital
Share Classes and Principal Shareholders
General Meeting and Voting Rights
Anti-Takeover Provisions
Amendments of Articles of Association
Transparency Directive
Dutch Financial Reporting Supervision Act
Dividends and Other Distributions
Financial Calendar 2023
Financial Review
Financial Review
Overview
Basis of Presentation
Capitalization and Indebtedness
Critical Accounting Estimates and Judgments
Results of Operation
Liquidity and Capital Resources
Off-Balance Sheet Arrangements
Contractual Obligations
Information Regarding the Independent Auditor
Material Contracts and Related Party Transactions
Employees
Legal and Arbitration Proceedings
Insurance
Financial Statements
Financial Statements
Consolidated Financial Statements
Consolidated Financial Statements
Consolidated Statements of Financial Position
Consolidated Statements of Profit or Loss
Consolidated Statements of Comprehensive Income and Loss
Consolidated Statements of Cash Flows
Consolidated Statements of Changes in Equity
Notes to the Consolidated Financial Statements
Notes to the Consolidated Financial Statements
1.
General Information about the Company
2.
Significant Accounting Policies
3.
Critical Accounting Judgements and Major Sources of Estimation Uncertainty
4.
Property, Plant and Equipment
5.
Intangible Assets
6.
Deferred Taxes
7.
Other Non-Current Assets
8.
Inventories
9.
Trade and Other Receivables
10.
Financial Assets — Current
11.
Cash and Cash Equivalents
12.
Share Capital and Share Premium
13.
Share-Based Payments
14.
Trade and Other Payables
15.
Product Net Sales
16.
Collaboration Revenue
17.
Other Operating Income
18.
Segment Reporting
19.
Research and Development Expenses
20.
Selling, General and Administrative Expenses
21.
Personnel Expenses
22.
Leases
23.
Financial Result and Exchange Gains/ (Losses)
24.
Income Tax Expense
25.
Loss per Share
26.
Financial Risk Management
27.
Related Party Transactions
28.
Contingencies
29.
Commitments
30.
Audit Fees
31.
Overview of Consolidation Scope
32.
Events After the Balance Sheet Date
Company Financial Statements
Company Financial Statements
Signatures of Executive and Non-Executive Directors
Company Financial Statements for argenx SE
Notes to the Company Financial Statements
Other Information
Independent Auditor’s Report
Non-Financial Information
Non-Financial Information
Regulations and Compliance
NFRD
EU Taxonomy
Patient Stories
Glossary
Glossary
Cross Reference table for annual reporting requirement
Management Confirmations
Definitions
Quick links
Patient Stories
Year 2022 in Brief
Outlook for Year 2023
Download center
argenx Group
argenx Group
Shareholder Letter
2022 In Brief
2023 Outlook
Company Profile
Strategy and Objectives
Our Products and Product Candidates
Our Products and Product Candidates
VYVGART
Efgartigimod Development
Efgartigimod Indications
ARGX-117 Development
Immunology Innovation Program
Collaboration Agreements
License Agreements
Distribution Agreements
Manufacturing and Supply
Intellectual Property
Regulation
Regulation
Licensure and Regulation of Biologics in the U.S.
Regulation and Procedures Governing Approval of Medicinal Products in the EU and the UK
Regulation and Procedures Governing Approval of Medicinal Products in Japan
Coverage, Pricing and Reimbursement
Government Pricing and Reimbursement Programs for Marketed Drugs in the U.S.
Healthcare Law and Regulation
Healthcare Reform
Environmental Issues which may Influence the Use of our Material Fixed Assets
Quick links
Patient Stories
Year 2022 in Brief
Outlook for Year 2023
Download center
Risk Factors
Risk Factors
Financial Position and Additional Capital
Commercialization
Other Government Regulations
Development and Clinical Testing
Dependence on Third Parties
Business and Industry
Intellectual Property
Organization and Operations
Quick links
Patient Stories
Year 2022 in Brief
Outlook for Year 2023
Download center
Corporate Governance
Corporate Governance
Dutch Corporate Governance Code
Management Structure
Management Structure
General
Statement of the Board of Directors
Board of Directors
Non-Executive Directors
Senior Management
Confirmation of No Past Offenses
Conflict-of-Interest Transactions
Code of Business Conduct and Ethics
Report of the Non-Executive Directors
Remuneration Report
Remuneration Report
Remuneration Policy
Reference Group and Setting Reward Levels
Remuneration Components of our Senior Management Team Compensation
Executive Remuneration
Remuneration of Non-Executive Directors
Pay Ratios Within the Company
Long-Term Incentives Granted to Key Persons – Equity Incentive Plan
Risk Appetite & Control
Quick links
Patient Stories
Year 2022 in Brief
Outlook for Year 2023
Download center
Share Capital
Share Capital
Legal Information on the Company
Share Capital
Share Classes and Principal Shareholders
General Meeting and Voting Rights
Anti-Takeover Provisions
Amendments of Articles of Association
Transparency Directive
Dutch Financial Reporting Supervision Act
Dividends and Other Distributions
Financial Calendar 2023
Quick links
Patient Stories
Year 2022 in Brief
Outlook for Year 2023
Download center
Financial Review
Financial Review
Overview
Basis of Presentation
Capitalization and Indebtedness
Critical Accounting Estimates and Judgments
Results of Operation
Liquidity and Capital Resources
Off-Balance Sheet Arrangements
Contractual Obligations
Information Regarding the Independent Auditor
Material Contracts and Related Party Transactions
Employees
Legal and Arbitration Proceedings
Insurance
Quick links
Patient Stories
Year 2022 in Brief
Outlook for Year 2023
Download center
Financial Statements
Financial Statements
Consolidated Financial Statements
Consolidated Financial Statements
Consolidated Statements of Financial Position
Consolidated Statements of Profit or Loss
Consolidated Statements of Comprehensive Income and Loss
Consolidated Statements of Cash Flows
Consolidated Statements of Changes in Equity
Notes to the Consolidated Financial Statements
Notes to the Consolidated Financial Statements
1.
General Information about the Company
2.
Significant Accounting Policies
3.
Critical Accounting Judgements and Major Sources of Estimation Uncertainty
4.
Property, Plant and Equipment
5.
Intangible Assets
6.
Deferred Taxes
7.
Other Non-Current Assets
8.
Inventories
9.
Trade and Other Receivables
10.
Financial Assets — Current
11.
Cash and Cash Equivalents
12.
Share Capital and Share Premium
13.
Share-Based Payments
14.
Trade and Other Payables
15.
Product Net Sales
16.
Collaboration Revenue
17.
Other Operating Income
18.
Segment Reporting
19.
Research and Development Expenses
20.
Selling, General and Administrative Expenses
21.
Personnel Expenses
22.
Leases
23.
Financial Result and Exchange Gains/ (Losses)
24.
Income Tax Expense
25.
Loss per Share
26.
Financial Risk Management
27.
Related Party Transactions
28.
Contingencies
29.
Commitments
30.
Audit Fees
31.
Overview of Consolidation Scope
32.
Events After the Balance Sheet Date
Company Financial Statements
Company Financial Statements
Signatures of Executive and Non-Executive Directors
Company Financial Statements for argenx SE
Notes to the Company Financial Statements
Other Information
Independent Auditor’s Report
Quick links
Patient Stories
Year 2022 in Brief
Outlook for Year 2023
Download center
Non-Financial Information
Non-Financial Information
Regulations and Compliance
NFRD
EU Taxonomy
Quick links
Patient Stories
Year 2022 in Brief
Outlook for Year 2023
Download center
Patient Stories
Quick links
Patient Stories
Year 2022 in Brief
Outlook for Year 2023
Download center
Glossary
Glossary
Cross Reference table for annual reporting requirement
Management Confirmations
Definitions
Quick links
Patient Stories
Year 2022 in Brief
Outlook for Year 2023
Download center
Home
Search
Search
Downloads
Facebook
Twitter
LinkedIn
E-Mail
